Frequency and E-field Enhancement of ITBS for Depression (FREED)

NARecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2025

Conditions
Major Depressive Disorder
Interventions
DEVICE

Transcranial Magnetic Stimulation (TMS) - Fully Individualized iTBS

Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the Ind-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting. The stimulation frequency will also be individualized according to EEG-derived TGC.

DEVICE

Transcranial Magnetic Stimulation (TMS) - targeted-iTBS

Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the targeted-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting.

DEVICE

Transcranial Magnetic Stimulation (TMS) - Standard-iTBS

Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. The standard iTBS will be delivered with the typical 5Hz/50Hz patterned frequencies used in the FDA approved treatment protocol and stimulation will be delivered according to the Beam F3 targeting.

Trial Locations (2)

2601

RECRUITING

Australian National University, Canberra

92093

RECRUITING

University of California, San Diego, La Jolla

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

University of California, San Diego

OTHER